All In Biotech

Free tool

FAERS Monitor: Duobrii

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209354 or its brand name (Duobrii, Halobetasol Propionate, Tazarotene). Reports on generic versions are filed under their own applications.

Reports

198

Serious

66

33% of reports

Hospitalization

13

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • psoriasis50
  • drug ineffective19
  • pruritus16
  • product dose omission issue15
  • headache14
  • nausea12
  • diarrhoea11
  • application site pain10
  • rash10
  • skin burning sensation10
  • off label use9
  • skin exfoliation9
  • application site erythema8
  • application site irritation8
  • erythema8

Reports by year received

View as table
YearReports
20171
201927
202031
202138
202235
202326
202420
202512
20268

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,961 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
application site irritationSignal868.334.7466
application site painSignal1048.226.4417
psoriasisSignal5040.732.01,907
application site erythemaSignal832.416.4213
skin burning sensationSignal1014.88.1116
skin exfoliationSignal911.36.075
product dose omission issueSignal155.43.350
pruritusSignal164.42.840
erythemaSignal84.12.116
rashSignal102.41.37
headacheSignal142.41.410
diarrhoea111.81.03
nausea121.60.92
drug ineffective191.51.03
off label use91.10.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.